« previous next »
Pages: [1]

Author Topic: (Lancet editorial) Towards equitable access to treatment for MS  (Read 10 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9552
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Lancet editorial) Towards equitable access to treatment for MS
« on: February 16, 2023, 09:40:21 am »
Editorial in the March 2023 issue of The Lancet Neurology, "Towards equitable access to treatment for multiple sclerosis":


https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00041-8/fulltext?dgcid=raven_jbs_etoc_email
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9552
  • MS diagnosed 1980
  • Location: Pacific Northwest
MS International Federation application to WHO for inclusion of 3 MS drugs in ESL
« Reply #1 on: March 26, 2023, 09:16:05 pm »
The MS International Federation's application to WHO (the World Health Organization) for inclusion of three MS treatments (Rituxan, glatiramer acetate, and Cladribine) in the Essential Medicines List (EML) can be seen here:




https://bit.ly/3FW7HSO
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
1 Replies
136 Views 		Last post April 07, 2017, 09:56:57 am
by agate
0 Replies
74 Views 		Last post September 22, 2017, 04:57:05 pm
by agate
0 Replies
93 Views 		Last post November 11, 2017, 09:36:06 am
by agate
0 Replies
29 Views 		Last post June 20, 2021, 07:30:09 am
by agate
0 Replies
10 Views 		Last post May 06, 2022, 10:40:34 am
by agate